LONDON (Alliance News) - Redx Pharma PLC on Monday reported a positive data from preclinical studies evaluating RXC004.
The results were presented at the National Cancer Research Institute 2018 Cancer Conference in Glasgow, Scotland.
RXC004 is a porcupine inhibitor, which has the potential to be used as a combination partner in immune-oncology treatment paradigms with immune-oncology agents such as anti-PD-1 checkpoint inhibitors.
"We are delighted to showcase some of the fantastic science happening at Redx," said Chief Scientific Officer Richard Armer.
"We are encouraged by the preclinical data presented at the National Cancer Research Institute, which demonstrates the exquisite sensitivity of specific genetically defined cancer models to our Porcupine inhibitor, RXC004," added Armer.
Redx shares were untraded on Monday, last quoted at 7.18 pence each.
